DB17229InvestigationalCell transplant therapies
PRGN-3006 are autologous CD3+ T cells genetically modified using a non-viral system to express a CD33 CAR, membrane-bound interleukin-15, and a truncated form of human HER1T (kill switch) on the...
- Also known as
- PRGN-3006 UltraCAR-T
- Code names
- PRGN-3006
What you can answer from here — as of April 23, 2025
Which companies are running trials of PRGN-3006, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account